X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1920) 1920
Book Review (275) 275
Publication (241) 241
Book Chapter (6) 6
Magazine Article (5) 5
Conference Proceeding (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1715) 1715
humans (1478) 1478
azacitidine - analogs & derivatives (814) 814
male (799) 799
oncology (791) 791
female (783) 783
azacitidine - administration & dosage (716) 716
azacitidine - pharmacology (635) 635
hematology (609) 609
aged (575) 575
dna methylation (570) 570
azacitidine - therapeutic use (560) 560
middle aged (558) 558
animals (521) 521
azacitidine (517) 517
cancer (513) 513
decitabine (429) 429
myelodysplastic syndromes - drug therapy (418) 418
methylation (378) 378
adult (371) 371
treatment outcome (370) 370
myelodysplastic syndromes (357) 357
acute myeloid-leukemia (305) 305
aged, 80 and over (302) 302
mice (300) 300
azacitidine - adverse effects (295) 295
leukemia, myeloid, acute - drug therapy (295) 295
dna methylation - drug effects (292) 292
antimetabolites, antineoplastic - therapeutic use (288) 288
myelodysplastic syndrome (282) 282
leukemia (277) 277
cell line, tumor (273) 273
antineoplastic combined chemotherapy protocols - therapeutic use (234) 234
antimetabolites, antineoplastic - administration & dosage (219) 219
chemotherapy (213) 213
care and treatment (208) 208
research (207) 207
5-azacytidine (200) 200
epigenetics (199) 199
5-aza-2'-deoxycytidine (196) 196
gene expression (188) 188
analysis (184) 184
expression (184) 184
acute myeloid leukemia (174) 174
dna (171) 171
prognosis (171) 171
therapy (171) 171
hematology, oncology and palliative medicine (168) 168
dose-response relationship, drug (166) 166
drug administration schedule (156) 156
antineoplastic agents (155) 155
article (154) 154
pharmacology & pharmacy (151) 151
antimitotic agents (150) 150
transplantation (150) 150
antimetabolites, antineoplastic - adverse effects (144) 144
apoptosis (142) 142
antimetabolites, antineoplastic - pharmacology (137) 137
conventional care regimens (137) 137
medicine & public health (137) 137
dna modification methylases - antagonists & inhibitors (133) 133
stem cells (132) 132
health aspects (131) 131
genetic aspects (130) 130
myelodysplastic syndromes - mortality (129) 129
rats (129) 129
survival (121) 121
antineoplastic agents - therapeutic use (120) 120
deoxyribonucleic acid--dna (118) 118
gene expression regulation, neoplastic - drug effects (118) 118
leukemia, myeloid, acute - mortality (117) 117
abridged index medicus (115) 115
genes (114) 114
myelodysplastic syndromes - genetics (114) 114
time factors (114) 114
aml (113) 113
cells (113) 113
phase-iii (113) 113
remission induction (113) 113
epigenesis, genetic (111) 111
mds (111) 111
promoter regions, genetic (110) 110
enzyme inhibitors - pharmacology (107) 107
older patients (105) 105
drug therapy (104) 104
retrospective studies (104) 104
cell biology (103) 103
apoptosis - drug effects (102) 102
tumors (102) 102
biochemistry & molecular biology (100) 100
myelodysplastic syndromes - pathology (100) 100
cell proliferation - drug effects (99) 99
gene-expression (99) 99
risk factors (99) 99
adolescent (97) 97
hypomethylating agents (97) 97
survival analysis (97) 97
epigenesis, genetic - drug effects (94) 94
myelodysplastic syndromes - therapy (92) 92
leukemia, myeloid, acute - genetics (90) 90
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1884) 1884
Chinese (18) 18
Japanese (11) 11
Russian (5) 5
French (4) 4
Spanish (3) 3
German (2) 2
Hebrew (1) 1
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 12/2017, Volume 268, pp. 92 - 101
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnormal blood... 
Bone marrow | Decitabine | Arsenic trioxide | Delivery | Nanoparticle | Myelodysplastic syndrome | APOPTOSIS | DNA METHYLATION | DRUG-DELIVERY | 5-AZACYTIDINE | COMBINATION | CANCER | CHEMISTRY, MULTIDISCIPLINARY | CHEMOTHERAPY | RETINOIC ACID | PHARMACOLOGY & PHARMACY | POLYMER HYBRID NANOPARTICLES | ACUTE PROMYELOCYTIC LEUKEMIA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Oxides - chemistry | Azacitidine - chemistry | Phosphatidylethanolamines - therapeutic use | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Alendronate - chemistry | Alendronate - therapeutic use | Tissue Distribution | Arsenicals - therapeutic use | Nanoparticles - therapeutic use | Bone and Bones - metabolism | Phosphatidylethanolamines - pharmacokinetics | Bone Marrow Cells - drug effects | Antineoplastic Agents - pharmacokinetics | Arsenicals - pharmacokinetics | Alendronate - pharmacokinetics | Myelodysplastic Syndromes - drug therapy | Oxides - administration & dosage | Azacitidine - administration & dosage | Oxides - therapeutic use | Cell Survival - drug effects | Arsenic Trioxide | Azacitidine - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Cells, Cultured | Polyethylene Glycols - pharmacokinetics | Azacitidine - analogs & derivatives | Mice, Transgenic | Phosphatidylethanolamines - administration & dosage | Antineoplastic Agents - chemistry | Polyethylene Glycols - administration & dosage | Oxides - pharmacokinetics | Arsenicals - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Arsenicals - chemistry | Nanoparticles - administration & dosage | Phosphatidylethanolamines - chemistry | Alendronate - administration & dosage | Azacitidine - therapeutic use | Medical research | Medical colleges | Medical examination | Arsenic | Analysis | Medicine, Experimental | Hematopoietic stem cells | Blood | Index Medicus | delivery | nanoparticle | decitabine | arsenic trioxide | bone marrow
Journal Article
Blood, ISSN 0006-4971, 07/2010, Volume 116, Issue 1, pp. 129 - 139
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 356 - 365
To test the safety and activity of 5‐aza‐2′‐deoxycytidine (decitabine) in patients with relapsed/refractory acute lymphocytic leukaemia ( ALL ), we conducted a... 
clinical trial | decitabine | precursor cell lymphoblastic leukaemia‐Lymphoma | DNA | methylation | DNA methylation | Clinical trial | Decitabine | Precursor cell lymphoblastic leukaemia-Lymphoma | precursor cell lymphoblastic leukaemia-Lymphoma | MECHANISMS | COMBINATION | CHEMOTHERAPY | EPIGENETICS | ACUTE LYMPHOBLASTIC-LEUKEMIA | ABERRANT DNA METHYLATION | DISEASE | MYELOID-LEUKEMIA | HEMATOLOGY | PHASE-I | P57KIP2 | Recurrence | Azacitidine - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | DNA, Neoplasm - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Hyperglycemia - chemically induced | Vincristine - administration & dosage | Adult | Female | Child | Chemical and Drug Induced Liver Injury - etiology | Azacitidine - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Azacitidine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Infusions, Intravenous | DNA Methylation - drug effects | Doxorubicin - adverse effects | Gastrointestinal Diseases - chemically induced | Azacitidine - therapeutic use | Index Medicus | DNA Methylation | Precursor Cell Lymphoblastic Leukaemia-Lymphoma | Clinical Trial
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1242 - 1248
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2670 - 2677
Journal Article
Annals of Hematology, ISSN 0939-5555, 11/2018, Volume 97, Issue 11, pp. 2253 - 2255
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00277-018-3354-1 
Medicine & Public Health | Hematology | Oncology | HEMATOLOGY | CHOP | CHEMOTHERAPY PLUS RITUXIMAB | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antigens, Neoplasm - biosynthesis | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Lymphoma, Large B-Cell, Diffuse - metabolism | Molecular Targeted Therapy | Cyclophosphamide - adverse effects | Rituximab - therapeutic use | Bendamustine Hydrochloride - administration & dosage | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Fatal Outcome | Vincristine - administration & dosage | Antimetabolites, Antineoplastic - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasms, Second Primary - genetics | Myelodysplastic Syndromes - drug therapy | Doxorubicin - administration & dosage | Antigens, Neoplasm - genetics | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Antigens, CD20 - genetics | Rituximab - administration & dosage | Rituximab - pharmacology | Azacitidine - pharmacology | Neoplasms, Second Primary - metabolism | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antigens, CD20 - biosynthesis | Vincristine - adverse effects | Neoplasms, Second Primary - drug therapy | Lymphoma, Large B-Cell, Diffuse - genetics | Doxorubicin - adverse effects | Azacitidine - therapeutic use | Lymphoma, Large B-Cell, Diffuse - chemically induced | Antimitotic agents | Medical colleges | Lymphomas | Antineoplastic agents
Journal Article
Cancer, ISSN 0008-543X, 07/2015, Volume 121, Issue 14, pp. 2375 - 2382
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2014, Volume 111, Issue 32, pp. 11774 - 11779
Impressive responses have been observed in patients treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anticytotoxic... 
T lymphocytes | Tumor cell line | Myeloid cells | Medical treatment | Antibodies | Epigenetics | Cellular immunity | Mice | Tumors | Cancer | Exome | 5-azacytidine | Entinostat | Methyltransferase | HDAC | methyltransferase | MULTIDISCIPLINARY SCIENCES | TUMOR | ANTIBODY | DEPLETION | MECHANISMS | PI3K-ALPHA | entinostat | exome | IMMUNOTHERAPY | INFLAMMATION | DNA METHYLTRANSFERASE | HISTONE DEACETYLASE INHIBITORS | T-CELLS | Mammary Neoplasms, Experimental - immunology | Immunotherapy - methods | Humans | Histone Deacetylase Inhibitors - administration & dosage | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Benzamides - administration & dosage | Colorectal Neoplasms - therapy | Neoplasm Metastasis - immunology | Myeloid Cells - immunology | Female | Myeloid Cells - drug effects | Epigenesis, Genetic - drug effects | Mammary Neoplasms, Experimental - secondary | Azacitidine - administration & dosage | Neoplasm Metastasis - therapy | Pyridines - administration & dosage | Combined Modality Therapy | CTLA-4 Antigen - immunology | Mammary Neoplasms, Experimental - therapy | Neoplasm Metastasis - genetics | Animals | Colorectal Neoplasms - immunology | Antibodies, Monoclonal - administration & dosage | Cell Line, Tumor | Colorectal Neoplasms - secondary | Mice, Inbred BALB C | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Rodents | Immunotherapy | Cytotoxicity | Metastasis | Polyclonal antibodies | Apoptosis | Index Medicus | Biological Sciences
Journal Article
Genes, Brain and Behavior, ISSN 1601-1848, 03/2017, Volume 16, Issue 3, pp. 313 - 327
DNA methylation is a major epigenetic process which regulates the accessibility of genes to the transcriptional machinery. In the present study, we... 
DNMT | inhibitor | DNA | methylation | prefrontal cortex | 5‐Aza‐2′‐deoxycytidine | methylome | cocaine self‐administration | cocaine self-administration | DNMT inhibitor | DNA methylation | 5-Aza-2′-deoxycytidine | 5-Aza-2 '-deoxycytidine | MEMORY FORMATION | BEHAVIORAL SENSITIZATION | KAPPA-B | NEUROSCIENCES | NUCLEUS-ACCUMBENS | GENE | CORTEX | BODY-SPECIFIC METHYLATION | BEHAVIORAL SCIENCES | EXPRESSION | BRAIN | PLASTICITY | Rats, Wistar | DNA Modification Methylases - antagonists & inhibitors | Epigenesis, Genetic | Cytidine - pharmacology | Male | Phosphatidylinositol 3-Kinases - metabolism | Cocaine-Related Disorders - genetics | Cytidine - analogs & derivatives | Brain - metabolism | DNA Methylation | Self Administration | Cocaine-Related Disorders - metabolism | Promoter Regions, Genetic | DNA Modification Methylases - metabolism | Enzyme Inhibitors - pharmacology | Reinforcement (Psychology) | Rats | Azacitidine - analogs & derivatives | Cocaine-Related Disorders - enzymology | DNA - genetics | Azacitidine - pharmacology | Cocaine - administration & dosage | Animals | CpG Islands | Genome | Animal experimentation | Epigenetic inheritance | Methyltransferases | Genes | Genomics | Monoclonal antibodies | Genomes | Cocaine | Genetic transcription | Methylation | Gene expression | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
Journal of Experimental and Clinical Cancer Research, ISSN 1756-9966, 06/2016, Volume 35, Issue 1, pp. 94 - 94
Background: Medulloblastoma (MB) is the most common pediatric brain tumor. Current treatment regimes consisting of primary surgery followed by radio-and... 
PROGENITOR CELLS | CANCER-CELLS | STEM-CELLS | DNA METHYLATION | ONCOLOGY | SUBEROYLANILIDE HYDROXAMIC ACID | TUMOR-SUPPRESSOR GENES | CYCLE ARREST | RHABDOID TUMOR | VALPROIC ACID | TRANS-RETINOIC ACID | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Stilbenes - administration & dosage | Humans | Epigenesis, Genetic - radiation effects | Antineoplastic Agents - administration & dosage | Stilbenes - pharmacology | Valproic Acid - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Medulloblastoma - radiotherapy | Radiation-Sensitizing Agents - administration & dosage | Hydroxamic Acids - administration & dosage | Neurogenesis - radiation effects | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Neurogenesis - drug effects | Medulloblastoma - genetics | Hydroxamic Acids - pharmacology | Azacitidine - administration & dosage | Tretinoin - pharmacology | Cell Differentiation - radiation effects | Dideoxynucleosides - administration & dosage | Cell Survival - drug effects | Dideoxynucleosides - pharmacology | Cerebellar Neoplasms - drug therapy | Tretinoin - administration & dosage | Radiation-Sensitizing Agents - pharmacology | Azacitidine - analogs & derivatives | Treatment Outcome | Combined Modality Therapy | Cerebellar Neoplasms - genetics | Cell Survival - radiation effects | Xenograft Model Antitumor Assays | Azacitidine - pharmacology | Animals | Valproic Acid - administration & dosage | Cell Differentiation - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Medulloblastoma - drug therapy | Cerebellar Neoplasms - radiotherapy | Cell Proliferation - radiation effects | Complications and side effects | Care and treatment | Ionizing radiation | Medulloblastoma | Research | Metastasis | Health aspects | Risk factors | Index Medicus
Journal Article